Hikma Pharmaceuticals (LON:HIK) Insider Buys £1,078,700 in Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Said Darwazah purchased 70,000 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was purchased at an average price of GBX 1,541 per share, with a total value of £1,078,700.

Said Darwazah also recently made the following trade(s):

• On Friday, November 7th, Said Darwazah purchased 60,000 shares of Hikma Pharmaceuticals stock. The shares were purchased at an average price of GBX 1,589 per share, for a total transaction of £953,400.

Hikma Pharmaceuticals Stock Up 0.6%

Shares of LON HIK opened at GBX 1,564.98 on Tuesday. The firm has a market cap of £3.47 billion, a PE ratio of 9.37, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a 50 day simple moving average of GBX 1,726.58 and a 200 day simple moving average of GBX 1,891.43. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. Hikma Pharmaceuticals PLC has a 1 year low of GBX 1,522 and a 1 year high of GBX 2,360.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a research report on Friday. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a report on Friday. Berenberg Bank reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a “buy” rating for the company in a research report on Thursday, November 6th. JPMorgan Chase & Co. reduced their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of GBX 2,416.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.